All News
Maui Potpourri (2.13.2026)
Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.
Read Article
RT @gibson_rheumPAC
Baseline serum urate >8–9 mg/dL strongly predicts worse flares, hospitalizations, and joint damage over years. Urate level should inform urgency and intensity of therapy. #RNL26 https://t.co/4RBVXZxCCX
Dr. John Cush RheumNow ( View Tweet)
“The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.”
- Martin Luther King, Jr.
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_rheumPAC
Arthur Kavanaugh’s RheumNow 2026: Why Do Plain X-Rays in Psoriatic Arthritis? Thought-provoking session on the role of plain radiographs in psoriatic arthritis—not as relics of the past, but as tools that still inform prognosis, function, and long-term
Dr. John Cush RheumNow ( View Tweet)
RT @gibson_RheumPAC
Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
GLP on Knee OA
STEP 9 Trial - 68 wk
Mean WOMAC improved by 41.7 pts, compared to 27.5 in PBO, improved SF-36
7% stopped due to side effects https://t.co/LJzGzzlgq6 https://t.co/5ybyUdfNjZ
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26 Haque
Effect of GLP1 on Pts with RA
Retrospective study
Significant reduction is RA disease activity (P=0.03), VAS pain (p<0.001), weight, cholesterol and A1c
But 1/3 stopped due to side effects (mostly GI) https://t.co/SNHTcRFmAX
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
#RNL26
Haque
TOGETHER-PsA -P3B study of IXE v IXE + Tirzepatide
BMI >27 + 1 wt related co-morbidity
-Endpts - ACR and >10% weight reduction
-ACR50 improved 33.5% compared to 20% IXE alone (p<0.05) https://t.co/KCpqbg3fHs https://t.co/zktIkdumDk
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
We have improved RA mortality in many areas but respiratory (mainly ILD) and infectious issues remain stubbornly elevated. #RNL26 https://t.co/ViucOIOOzY https://t.co/3kIqPMeKKX
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAConway
AUC of various published screening strategies for RA-ILD. We often say 0.80 is an acceptable cut off but ideally would like a bit better #RNL26 https://t.co/L19uJ7ETwc
Dr. John Cush RheumNow ( View Tweet)
RT @RichardPAConway
Odds ratios for ILD in early RA from SAIL-RA study. Again disease activity stands out. #RNL26 https://t.co/9cXjOFl3Th
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
Drug-induced SCLE remains an important mimic in biologic-treated patients. Compared with idiopathic SCLE, drug-induced disease is often more widespread and may resolve with antibody normalization after withdrawal.#RNL26 https://t.co/ICOzg3Tz4L
Dr. John Cush RheumNow ( View Tweet)
RT @Gibson_RheumPAC
Important rheumatology signal: dupilumab-associated inflammatory arthritis. Usually seronegative, imaging-supported, and sometimes persistent despite normal labs. Co-management and careful work-up are essential.#RNL26 https://t.co/r73cSZC59s
Dr. John Cush RheumNow ( View Tweet)
RT @@Gibson_RheumPAC
Eczematous eruptions with IL-17 inhibition are increasingly recognized. Registry data suggest higher adjusted incidence with IL-17 inhibitors compared with other biologic classes, especially in older patients and those with atopic history. #RNL26 https://t.co/nvwl5mNg4k
Dr. John Cush RheumNow ( View Tweet)
Incretins/GLP-1s are being investigated widely. @RWCSmtg #RWCS26 https://t.co/57JzRJfK8l
Dr. John Cush RheumNow ( View Tweet)
Most inhibition of inflammation is via the brain. More GLP1 and GIP1 receptors are in the brain, more than the gut. @RWCSmtg #RWCS26 https://t.co/CNzUqteBLg
Dr. John Cush RheumNow ( View Tweet)
The hx and timeline of GLP1a development. @RWCSmtg #RWCS26 https://t.co/7tPgcRy4Ze
Dr. John Cush RheumNow ( View Tweet)
Dr. Willa Tsueh taking on hx of GLP-1 agonists. The first ones, Victoza and Tulicity go back to 2010. @RWCSmtg #RWCS26 https://t.co/cKiDCM5xw6
Dr. John Cush RheumNow ( View Tweet)
#RNL26
Haque @HopkinsRheum
1/2 of Americans will be obese by 2030
"Obesity is common & obesity is expensive"
Adipose tissue - active endocrine organ -> cytokines, chemokines, adipokines
Leads to inflamm axis - risk factor similar to 🚬, higher activity, worse response https://t.co/yQLTpE7reY
Dr. John Cush RheumNow ( View Tweet)
